Quest Diagnostics Incorporated has been awarded several contracts by the U.S. Centers for Disease Control and Prevention $(CDC)$ to bolster testing and sustained laboratory readiness for emerging infectious diseases. These contracts, awarded in September 2024, include funding for the development of diagnostics to detect the Oropouche virus. The funding will ensure Quest Diagnostics maintains testing readiness, including having adequate supplies of equipment and chemical reagents, to rapidly mobilize a response if needed to safeguard public health. Additionally, Quest has launched the first commercially available diagnostic test for Avian Influenza A H5, supported by this funding.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.